Serum Institute of India Ltd. (SII Ltd., Pune, India, www.seruminstitute.com) has developed a vaccine against Hib (Haemophilus influenza type b) and obtained a license from the Indian Government for its production.
Serum Institute of India Ltd. (SII Ltd., Pune, India, www.seruminstitute.com) has developed a vaccine against Hib (Haemophilus influenza type b) and obtained a license from the Indian Government for its production. The pilot process technology know-how came from the Netherlands Vaccine Institute (NVI, Bilthoven, the Netherlands, www.nvi-vaccin.nl). This is the first time that through intensive joint development and technology transfer a developing country vaccine manufacturer has developed a Hib vaccine successfully and obtained a license for it.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.